A Phase 3 interventional study of Dexamethasone Phosphate Ophthalmic Solution and Prednisolone Acetate Ophthalmic (1%) in Anterior Uveitis, sponsored by Eyegate Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 12 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-07-26.
Sponsored by Eyegate Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Uveitis, Anterior with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Uveitis, Anterior · United States.
Among the 30 studies in Uveitis, Anterior with a site in United States, this one has the largest enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2016, is one of 9 in phase 3, and was the 14th registered.
56 studies on the registry are indexed under Uveitis, Anterior; 9 are open to participants now.
Browse Uveitis, Anterior studies →5 of the 30 studies in Uveitis, Anterior with a site in United States are open now. Recruiting first, the newest first:
Oregon Health and Science University · Sites in United States
Ages 5–85 · Healthy volunteers
Massachusetts Eye Research and Surgery Institution · Sites in United States
Ages 18+ · Healthy volunteers
University of California, San Francisco · Sites in United States, Taiwan, Thailand
Ages 18+ · Healthy volunteers
Nisha Acharya · Sites in United States, Italy, United Kingdom
Ages 2+
CARE ARTHRITIS LTD. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Uveitis, Anterior studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 12 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 11 · Phase 4 4
First in 2005; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 251 is above the median of 50 across 45 interventional studies indexed under Uveitis, Anterior.
Median enrollment 40 across the 27 interventional studies, 50 across the 3 observational. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 30 have an industry lead sponsor. The 10 most frequent:
Eyegate Pharmaceuticals, Inc. is the lead sponsor of 13 studies on the registry; none are open to participants now.
Eyegate Pharmaceuticals, Inc. has 3 studies filed under Uveitis, Anterior — fewer than ten, so there is no comparison to draw.
2 of the studies in Uveitis, Anterior with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07285070Novaliq GmbHTacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis | 2026-12 |
| NCT07018206CARE ARTHRITIS LTD.Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Uveitis, Anterior with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.
This will be a Phase 3, randomized, double-masked, parallel arm, positive-controlled non-inferiority study, in which up to 250 subjects (approximately 125 subjects per treatment arm) will be enrolled at up to 60 clinical sites. Patients with non-infectious anterior segment uveitis who are interested in participating in the study will be provided an informed consent form prior to screening. Screening/Baseline procedures which include BCVA, slit lamp examination, fundus exam, IOP by tonometry will be used to determine eligibility.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dexamethasone phosphate ophthalmic solution (40 mg/mL)
Drug: Dexamethasone Phosphate Ophthalmic Solution
Prednisolone Acetate Ophthalmic (1%)
Drug: Prednisolone Acetate Ophthalmic (1%)
40 mg/mL
Also known as: EGP-437
Prednisolone Acetate (1%)
Also known as: Pred Acetate (1%)
Proportion of subjects with an AC cell count of zero at Day 14
Time frame: Day 14 ± 2 days
Plan to share: Yes
No publications or documents are linked to this record.
Ran from Jan 2016 to primary completion in Apr 2018, 27 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone phosphate
Eyegate Pharmaceuticals, Inc.